Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges  by Ha, Dinh et al.
Institute of Materia Medica, Chinese Academy of Medical SciencesChinese Pharmaceutical Association
www.elsevier.com/locate/apsb
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2016;6(4):287–296http://dx.doi.org/10.10
2211-3835 & 2016 Ch
Elsevier B.V. This is
Abbreviations: ALIX
of differentiation; DIL
EGFR, epidermal grow
extracellular vesicle; H
mobility group AT-h
lipopolysaccharides; M
phagocyte system; mR
PEG, polyethylene gly
TNF-α, tumor necrosi
nCorresponding auth
E-mail address: v
1Present address: LE
Peer review under rwww.sciencedirect.comREVIEWExosomes as therapeutic drug carriers and
delivery vehicles across biological membranes:
current perspectives and future challengesDinh Ha, Ningning Yang1, Venkatareddy NadithenManchester University, College of Pharmacy, Natural & Health Sciences, Fort Wayne, IN 46845, USA
Received 23 December 2015; received in revised form 19 January 2016; accepted 26 January 2016KEY WORDS
Exosomes;
Nanocarrier;
Extracellular vesicles;
Drug delivery systems16/j.apsb.2016.02.00
inese Pharmaceutica
an open access artic
, ALG-2 interacting
, 1,10-dioctadecyl-3
th factor receptor;
EK293, human emb
ook protein; Hsp,
APK-1, mitogen-a
NA, messenger RN
col; RNA, ribonucle
s factor α; TSG101,
or. Tel.: þ260 470
nadithe@mancheste
COM School of Ph
esponsibility of InstAbstract Exosomes are small intracellular membrane-based vesicles with different compositions that are
involved in several biological and pathological processes. The exploitation of exosomes as drug delivery
vehicles offers important advantages compared to other nanoparticulate drug delivery systems such as
liposomes and polymeric nanoparticles; exosomes are non-immunogenic in nature due to similar
composition as body's own cells. In this article, the origin and structure of exosomes as well as their
biological functions are outlined. We will then focus on speciﬁc applications of exosomes as drug delivery
systems in pharmaceutical drug development. An overview of the advantages and challenges faced when
using exosomes as a pharmaceutical drug delivery vehicles will also be discussed.
& 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1
l Association and Institute of Materia
le under the CC BY-NC-ND license
protein X; ATPase, adenosine tripho
,3,30,30-tetramethylindocarbocyanine
EpCAM, epithelial cell adhesion mo
ryonic kidney cell line 293; HeLa, H
heat shock proteins; IL-6, interleu
ctivated protein kinase 1; MHC, maj
A; MVB, multi-vesicular body biogen
ic acid; ROS, reactive oxygen specie
tumor susceptibility gene 101; VPS4
2748.
r.edu (Venkatareddy Nadithe).
armacy, 5000 Lakewood Ranch Blv
itute of Materia Medica, Chinese AcMedica, Chinese Academy of Medical Sciences. Production and hosting by
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
sphatase; BBB, blood–brain barrier; CCK-8, cell counting kit-8; CD, cluster
perchlorate; DNA, deoxyribonucleic acid; EGF, epidermal growth factor;
lecule; ESCRT, endosomal sorting complexes required for transport; EV,
enrietta Lacks cells; HIV, human immunodeﬁciency virus; HMGA2, high-
kin-6; ILVs, intraluminal vesicles; kRAS, Kirsten rat sarcoma; LPS,
or histocompatibility complex; miRNA, micro RNA; MPS, mononuclear
esis; PBMC, peripheral blood mononuclear cells; PD, Parkinson’s disease;
s; RPE1, retinal pigment epithelial cells 1; siRNA, small interference RNA;
, vacuolar protein sorting-associated protein 4
d, Bradenton, FL 34211, USA.
ademy of Medical Sciences and Chinese Pharmaceutical Association.
Dinh Ha et al.2881. Introduction
Intercellular communication is absolutely essential to cell devel-
opment and the maintenance of homeostasis in multicellular
organisms. These communications between cells can be localized
or distant. Local communication involves direct contact between
cells facilitated through communication systems, like a gap
junction that connects the cytoplasm of cells adjacent to one
another, allowing signaling substances to pass between the cells.
On the other hand, distant intercellular communication is facili-
tated by molecules like hormones that send signals through
circulatory system to other parts of the body. Another case of
distant intercellular communication also occurs in extracellular
vesicle (EV), which is a membrane-based structure. These EVs
serve as vehicles to carry different types of cellular cargo—such as
lipids, proteins, receptors and effector molecules—to the recipient
cells1.
There are three types of EVs that are differentiated based on
their intracellular origins: apoptotic bodies, microvesicles and
exosomes2. Apoptotic bodies have a size ranging from 50 to
5000 nm and contain cellular contents such as deoxyribonucleic
acid (DNA), ribonucleic acid (RNA) and histone proteins. During
apoptosis, apoptotic bodies present these contents to marcro-
phages, which results in cell engulfation3,4. Other types of EVs
known as microvesicles are also referred to as ectosomes,
shedding vesicles, microparticles, plasma membrane-derived vesi-
cles, and exovesicles. Microvesicles are formed through the
outward budding and ﬁssion from plasma membranes, with a size
ranging from 50 nm to 1000 nm. Once microvesicles are formed,
they carry speciﬁc proteins and lipids and then deliver their
cargoes to designated recipient cell2. The ﬁnal category of EVs
is exosomes, which differ from microvesicles mainly in terms of
their intracellular origin and size (Fig. 1).
Over the past decades, there has been extensive research carried
out on exosomes. The word “exosome” was ﬁrst used in 1970 by
Rose Johnstone and her colleagues5. While working with maturing
reticulocytes, they observed the formation of “an intracellular sac
ﬁlled with small membrane-enclosed structure of nearly uniform
size”. These formed intracellular vesicles and released contents
outside the cell, as opposed to inside of cell (endocytosis), where
external molecules are internalized into the membrane-bound
structure. Hence, these intracellular-formed vesicles were named
“exosome”5.
Exosomes are originated from endosomes with a smaller size,
ranging from 40 to 100 nm6. They are secreted by all cell types
and can be found in most body ﬂuids, including blood, saliva, and
urine. An exosome is a “nanosphere” with a bilayerd membrane,
containing various types of lipids and proteins derived from the
parent cell. Some of these proteins include transport proteins, heat
shock proteins, proteins associated with multi-vesicular bodyFigure 1 Types of microvesicles. Exosome with sizes ranging 40–
100 nm (left), microvesicles with sizes ranging 50–1000 nm (middle),
apoptotic body size ranging 50–5000 nm (right).biogenesis (MVB), and tetraspanin. In addition to proteins,
exosomes are comprised of different types of lipids, such as
cholesterol, sphingolipids, phosphoglycerides, ceramides, and
saturated fatty acid chains7. The composition of exosomes is
critical since they serve as a biomarker and provide an indication
of its function in biological processes.
1.1. Formation of exosomes
In general, the formation of exosomes consists of three different
stages: (1) the formation of endocytic vesicles from plasma
membrane, (2) the inward budding of the endosomal vesicle
membrane resulting in MVBs that consist of intraluminal vesicles
(ILVs), and (3) the fusion of these MVBs with the plasma
membrane, which releases the vesicular contents, known as
exosomes7 (Fig. 2). In the ﬁrst stage, endocytic vesicles are
formed from the plasma membrane, creating an early endosome,
which is then matured into late endosomes. The limiting mem-
brane of these late endosomes undergoes inward budding, in turn
forming vesicles inside the lumen. The accumulation of these ILVs
inside the late endosomes is termed as MVBs. There are two
known pathways to the formation of MVBs. One pathway
involves endosomal sorting complexes required for transport
(ESCRT) and another pathway is ESCRT independent. These
MVBs can either fuse with lysosome for degradation or fused with
the plasma membrane of the cell, releasing ILVs into extracellular
space and these released ILVs are exosomes8.
The ESCRT consists of four soluble multi-protein com-
plexes named ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III.
The complex is recruited to sort selected proteins into ILVs.
ESCRT-0 is responsible for cargo clustering, which is required
for the ubiquitination of endocytosed receptors9. These cargoes
constitute proteins that will be incorporated into ILVs and, later,
become part of the released exosomes. Tumor susceptibility gene
101 (TSG101), a component of ESCRT-I, forms a complex with the
ubiquinated cargo protein and helps in the activation of ESCRT-II
complex, inducing its bud formation. This complex then involvesFigure 2 Formation of exosome and microvesicle. Exosome is
derived from endosome formed from plasma membrane. As early
endosome becomes late endosomes, inward budding occurs and forms
multivesicular bodies (MVB) containing numerous intraluminal vesi-
cles (ILV). MVB can either get degraded by lysosomes or fuse with
the membrane to release ILV called exosomes. Micorvesicles, on the
other hand, originate from the budding of the plasma membrane.
Table 1 Summary and examples of exosomal compositions.
Exosome
composition
Example
Proteins Heat shock proteins: Hsp70, Hsp90
Membrane transport and fusion proteins:
GTPase, annexins, ﬂotillin
Tetraspanins: CD9, CD63, CD81, CD82
Thrombospondin
ALIX
TSG101
Lipids Sphingomyelin
Phosphatidylcholine
Phosphatidylethanolamine
Phosphatidylserine
GM3
Phosphatidylinositol
Nucleic acids mRNA
miRNA
Non-coding RNA
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ubiquitination enzyme to remove the ubiquitin from the cargo
proteins before sorting them into ILVs. In the last stage, ESCRT-III
gets disassembled by vacuolar protein sorting-associated protein 4
(VPS4) adenosine triphosphatase (ATPase)10,11.
Studies have shown that molecules that inhibit ESCRT can also
inhibit exosome secretion. For example, four independent studies
have demonstrated that inhibiting the HRS member of ESCRT-0
resulted in decreased exosome secretion in various cell types,
including Henrietta Lacks cells (HeLa)—a lineage of cancer
human epithelial cells, mouse dentritic cells, human embryonic
kidney cell line 293 (HEK293), and squamous carcinoma
cells12–15. Other studies have shown that the depletion of
TSG101 also reduced exosome secretion in tumor cells and in
immortalized retinal pigment epithelial cells 1(RPE1)12,16. In
addition, several studies have shown the formation of exosomes
despite the inhibition of ESCRT, indicating the existence of an
ESCRT independent pathway. This independent mechanism
involves molecules such as lipids, tetraspanins, or heat shock
proteins17. It has been proposed that lipids such ceramides induce
the inward curvature of the limiting membrane of MVBs to form
ILVs. Other lipids associated with the formation of exosomes
through ESCRT independent mechanisms are cholesterol and
phosphophatidic acid. Besides lipids, proteins such as tetraspanins
have also been associated with cargo sorting for exosomes18 and
the incorporation of melanosomal proteins into ILVs in an
ESCRT-independent manner19.
1.2. Isolation and characterization of exosomes
Exosomes are isolated in cell culture studies using several different
techniques. The most common isolation technique is differential
centrifugation, whereby large particles and cell debris in the
culture medium are separated using centrifugal force between
200–100,000 g and the exosomes are separated from supernatant
by the sedimenting exosomes at 100,000 g20–22. However, this
technique is not precise in purifying exosomes and, thus, the
resulting exosome extractions tend to contain aggregates of
cellular proteins and particulates from the cell culture medium23.
In addition, this technique is time consuming and requires
specialized equipment. Exosome purity can be improved, however,
by centrifuging the samples using ﬂotation density gradient
centrifugation with sucrose or Optiprep, which results in highly
puriﬁed and enriched exosomes1,24.
Another common technique for exosome isolation is the
monoclonal antibody based method. Antibodies against
exosome-associated antigens—such as cluster of differentiation
(CD) molecules CD63, CD81, CD82, CD9, epithelial cell adhe-
sion molecule (EpCAM), and Ras-related protein (Rab5)—are
used for separation1,24. The antibodies can be immobilized in
different media conditions and combined with magnetic beads,
chromatographic matrix, plates, and microﬂuidic devices for
separation24. A drawback to this technique, however, is that
non-exosomes vesicles that carry the antigens also bind to the
antibody, reducing the purity of the extracted exosomes1. Ultra-
ﬁltration is another way to isolate exosomes based on their size
differences. This method is less time consuming compared to
ultracentrifugation and does not require special equipment7. One
alternative method for isolating exosomes based on size is using
high performance liquid chromatography. Exosomes prepared by
this technique provide highly puriﬁed exosomes. However, this
technique also requires expensive equipment1,7. Overall, there isno single ideal isolation and puriﬁcation method that is highly
selective for exosomes.
Exosomes can be characterized based on their size, protein
content, and lipid content. Exosomes are sphere-shaped structures
with sizes between 40–100 nm and are much smaller compared to
other systems, such as a microvesicle, which has a size range from
100–500 nm. Several methods can be used to characterize
exosomes, including ﬂow cytometry, nanoparticle tracking analy-
sis, dynamic light scattering, western blot, mass spectrometry, and
microscopy techniques25. Exosomes can also be characterized and
marked based on their protein compositions, with intergrins and
tetraspanins being the two most abundant proteins found in
exosomes. Other protein markers include TSG101, ALG-2 inter-
acting protein X (ALIX), ﬂotillin 1, and cell adhesion molecules.
Similar to proteins, lipids are major components of exosomes and
can be utilized to characterize them.
1.3. Composition of exosomes
The nanospherical membrane-type structure of exosomes is
formed with a bilayer of lipids. It is also composed of various
types of lipids and proteins (Table 1) that are derived from the
parent cells from which the exosome is formed (Fig. 3). According
to ExoCarta, an exosome database, there are currently around 8000
proteins and 194 lipids known to be associated with exosomes24.
Since exosomes originate from the intracellular component
“endosome”, they contain proteins such as heat shock proteins
(Hsp70 and Hsp90), membrane transport and fusion proteins
(GTPases. Annexins and ﬂotillin), and tetraspanins (CD9, CD63,
CD81, and CD82)24. Among these proteins, heat shock proteins,
annexins, and proteins of the Rab family are abundantly detected in
exosomes and are involved in their intracellular assembly and
trafﬁcking. Tetraspanins, a family of transmembrane proteins, are
another protein commonly detected in exosomes. In a cell, tetra-
spanins mediate fusion, cell migration, cell–cell adhesion, and
signaling. However, in exosomes, their function remains largely
unknown2. Another abundant protein found in exosomes is integ-
rins, which are adhesion molecules that facilitate cell binding to the
extracellular matrix. In exosomes, integrins are involved in adhering
the vesicles to their target cells26. All these proteins have been used
as positive markers to detect the presence of exosomes. Other
Figure 3 Composition of exosomes. Exosomes are composed of
various types of proteins, such as major histocompatibility complex
(MHC)-II, integrin, cluster of differentiation (CD), tetraspanins, heat
shock protein (Hsp), Ras-related protein (Rab), etc. Exosomes also
contain various types of lipids, such as sphingomyelin and cholesterol.
Lastly, exosomes are found to contain nucleic acid, including miRNA,
mRNA and non-coding RNAs.
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CD59, lactadherin, ALIX, and TSG1012,27. These different types of
proteins become incorporated into exosomes during exosome
formation and serve as cargo for cell–cell communication.
Besides proteins, exosomes are also rich in lipids, with different
types of exosomes containing different types of lipids. The lipid
bilayer of exosomes is mainly constituted of cell plasma mem-
brane types of lipids such as sphingomyelin, phosphatidylcholine,
phosphatidylethanolamine, phosphatidylserine, monosialotetrahex-
osylganglioside (GM3), and phosphatidylinositol28. Sphingomye-
line and GM3 are responsible for determining the exosome's
rigidity29 while phosphatidylserine is expressed on the plasma
membrane of exosomes through different types of phospholipid
transportation enzymes. It is involved in docking the outer
proteins, allowing the signaling and fusion of the exosome to
the plasma membrane30. Other types of lipids that can form
exosomes are cholesterol, ceramide, and phosphoglycerides, along
with saturated fatty-acid chains. Additional constituents of exo-
somes include nucleic acids such as micro RNA (miRNA),
messenger RNA (mRNA), and non-coding RNAs24.1.4. Biological functions of exosomes
Exosomes are secreted by many different types of cells through
biological ﬂuids, including synovial ﬂuid, breast milk, blood,
urine, saliva, amniotic liquid, and in-blood serum7, suggesting that
they play a major role in intercellular communication and
triggering physiological responses. Exosomes are found ﬁrst to
be involved in removing unnecessary proteins during the cell
maturation process31,32. Depending on the origin of the exosomes,
they have different functions. For example, studies have found that
exosomes derived from antigen presenting cells have the ability to
express major histocompatibility complex (MHC) class I and II
molecules on the cell surface, which helps in activating CD8þ andCD4þ T-cells to induce speciﬁc immune responses26,33,34. By
carrying prostaglandins, exosomes secreted by platelets are
involved in the inﬂammatory response18. Besides exchanging
proteins and lipids between recipient cells, exosomes are shown
to carry a nucleic acid type of cargo, with exosomes secreted by
mast cells containing mRNA and small RNA, which then gets
transferred to targeted recipient cells and translated into the
recipient cell35. Glioblastoma cells also secret exosomes contain-
ing mRNA, miRNA, and angiogentic proteins to microvascular
endothelial cells, stimulating angiogenesis36. In general, the
functions of exosomes facilitate cell-to-cell communication in a
target-speciﬁc manner throughout the body. Currently, it is known
that exosomes are involved in many biological processes, includ-
ing the maturation of erythrocytes, the elimination of unnecessary
proteins and RNA37, antigen presentation in immune responses38,
coagulation, inﬂammation, and angiogenesis7. Exosomes are also
found to have the ability to transfer horizontal miRNA6. These
processes are facilitated through the exosome's cargo function,
with each exosome's composition based on the source of the
parental cell, from which it is derived.
Besides involving normal biological process, exosomes are
found to be associated with many common diseases. In cancer, for
example, exosomes are found to induce a pro-tumoral microenvir-
onment by transferring mRNA and protein, such as mutant Kirsten
rat sarcoma (kRAS) viral oncogene protein and c-Met oncoprotein,
to distant sites, thus promoting angiogenesis, thrombosis, and
tumor cell proliferation39–41. In neurodegenerative disease, such as
Parkinson's disease (PD), exosomes are found to be responsible for
transporting misfolded proteins from unhealthy neurons to nearby
cells, thus spreading the disease from cell to cell42. Exosome
involvement is also observed in other diseases, such as myocardial
infraction and human immunodeﬁciency virus (HIV), a type of
cardiovascular disease and infectious disease, respectively.
Given that exosomes can be isolated from almost any cell, are
involved in cell-to-cell communication, and participate in both
normal and pathobiological mechanisms, there have been exten-
sive studies exploiting their use both as diagnostics and therapeu-
tics. For example, exosomes are used to detect tumors in patients
with prostate, breast, and ovarian cancers43–45. In infectious
disease, they carry and express infectious RNA and proteins,
which allows for the diagnosis of infectious diseases as well as the
detection of active and latent forms of intracellular infection24. In
terms of therapeutics, exosomes are shown to have the ability to
induce tissue regeneration by delivering growth factors, proteins,
miRNA, mRNA, non-coding RNA, and lipids. For example, in a
myocardial infarction and kidney injury model, exosomes derived
from stem cells and endothelial progenitor cells have been able to
regenerate cardiac tissue and neovascularization.2. Exosomes as drug delivery vehicle
Currently, the most preferred drug delivery systems are liposomes
and polymeric nanoparticles. A liposome is a synthetic vesicle
with a phospholipid membrane that self-assembles into various
sizes and shapes in an aqueous environment46. Polymeric nano-
particles are drug delivery systems that help in the entrapment,
encapsulation, or attachment of drug molecules47. Both of these
delivery systems have been used to deliver different types of drug
molecules, including anti-cancer drugs, anti-fungal drugs, and
analgesics. However, the ability of an ideal liposome to evade the
host immune system with a long circulating capability, with
Table 2 Summary of studies conducted using exosomes as drug delivery system.
Research Aim Ref. (Author, Year)
Small molecules Using exosomes to improve delivery of curcumin Sun, 201053
Delivery of doxorubicin into tumor tissue Tian, 201454
Deliver paclitaxel and doxorubicin across blood–brain barrier Yang, 201555
Protein Deliver catalase across BBB to treat PD Haney, 201556
Nucleic Acids
siRNA Human exosomes to deliver siRNA into T cells Wahlgren, 201257
Exosomes to deliver siRNA into HeLa & Fibrosarcoma cell line (HT1080 cells) Shtam, 201358
Delivery of siRNA using endothelial derived exosomes Banizs, 201459
miRNA Exosome to antitumor miRNA into breast cancer cells Ohno, 201360
Figure 4 Formation of exosomal curcumin. Curcumin was incorporated into murine tumor cell line (EL-4), derived exosomes and isolated using
sucrose gradient centrifugation.
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hand, polymeric nanoparticles may have better stability than
liposomal systems, but their biocompatibility and long-term
potential safety remain a concern49. In these cases, exosomes or
exosome mimetics50—with many of the desirable features of an
ideal drug delivery system, such as a long circulating half-life, the
intrinsic ability to target tissues, biocompatibility, and minimal or
no inherent toxicity issues51—appear to be a superior choice,
overcoming the limitations observed with the majority of liposo-
mal or polymeric drug delivery systems52. Table 2 summarizes the
studies conducted using exosomes as drug delivery system.2.1. Exosomes as drug delivery vehicles for small molecules
Extensive research has been done using exosomes as vehicles for
therapeutic drug delivery. One study involved the use of exosomes
to deliver curcumin and treat an inﬂammatory disease53. Curcumin
is a natural polyphenol found in the rhizomes of turmeric and it
has anti-inﬂammatory, antineoplastic, antioxidant, and chemo-
preventive properties61–63. Exosomes are employed to form a
complex with curcumin for the purpose of enhancing curcumin's
effectiveness. Clinical trials have also shown its efﬁcacy and safety
for cancer patients64. However, its low solubility due to its
hydrophobic nature and preferential interaction with lipid mem-
branes reduces its bioavailability65.
In this study, curcumin was incorporated into exosomes by
mixing curcumin with murine tumor cell line (EL-4) derived
exosomes and subjecting it to a sucrose-gradient centrifugation.
Exosomal protein markers such as TSG101 and CD81 were used
to speciﬁcally identify the exosome curcumin complex (Fig. 4).
Various experiments were then carried out to show the incorpora-
tion of curcumin into the exosome while increasing its solubility,
stability, and bioavailability. The anti-inﬂammatory activity of
exosomal curcumin was also assessed both in vitro and in vivo.
In vitro, marcophages treated with exosomal curcumin producedsigniﬁcantly fewer inﬂammatory cytokines such as interleukin-6
(IL-6) and tumor necrosis factor α (TNF-α) compared to macro-
phages treated with curcumin alone, indicating that exosomal
curcumin enhances anti-inﬂammatory activity. In vivo, an lipopo-
lysaccharides (LPS)-induced septic shock animal model was used,
and mice treated with exosomal curcumin showed signiﬁcant
survival compared to mice treated with only curcumin. Finally, the
study showed that exosomal curcumin decreased the number of
CD11bþGr-1þ cells, a type of cell that increases a response to
LPS-induced septic shock in the lungs and leads to acute lung
inﬂammation53. In general, this study showed the ability of
exosomes to carry highly hydrophobic drugs, such as curcumin,
enhancing their anti-inﬂammatory effects.
Besides enhancing the properties of drugs, exosomes are also
employed to carry small molecular drugs across the blood–brain
barrier (BBB). Indeed, 98% of potent central nervous system drugs
cannot cross the BBB and their conceptual efﬁcacy shown in labs
have not been successful in clinical trials66. Many Nano-
formulations have been employed to solve the problems associated
with the permeability of drugs across the BBB. However, other
problems, such as nano-toxicity and rapid drug clearance by the
mononuclear phagocyte system (MPS), have also been observed67.
To compensate for these complications, polyethylene glycol (PEG)
has been introduced to decrease MPS drug uptake. However, this
resulted in reduced interaction between target cells, consequently
decreasing drug distribution in the brain68,69. In this case,
exosomes, a natural product of the body’s own cells, can be
tailored to cross the BBB, thus improving drug transport to the
brain by decreasing MPS drug clearance (Fig. 5).
Meanwhile, research has been carried out encapsulating antic-
ancer drugs such as paclitaxel and doxorubicin into exosomes,
showing the potential of exosomes for brain delivery across the
BBB and explaining their transport mechanisms, using zebraﬁsh
as an animal model55. In that study, exosomes were isolated
from various cell lines, including gliobastoma astrocytoma U-87
MG, endothelial bEND.3, neuroectodermal tumor PFSK-1, and
Figure 5 Ability of exosome and its drug contents to cross the blood–brain barrier.
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protein isolation kit. Exosomes were loaded with rhodamine 123
and paclitaxel or doxorubicin through mixing and incubation.
Experiments were then performed to characterize the isolated
exosomes, the cellular uptake of the exosomes containing rhoda-
mine 123, and the cytotoxicity of the delivered anticancer drugs
within the exosomes of U-87 MG and bEND.3 cells. In vivo, the
ability of exosomes to deliver drugs across the BBB was examined
by injecting bEND.3-derived exosomes loaded with rhodamine
123 and doxorubicin, or paclitaxel, in zebraﬁsh embryos. At the
end of the experiments, brain tissue was examined for the presence
of rhodamine 123 ﬂuorescence. The results undeniably showed the
drug's distribution in the brain region of the zebraﬁsh embryos,
suggesting the ability of exosomes to deliver drugs across the
BBB. In subsequent experiments, a primary brain cancer model
was developed using zebraﬁsh and anticancer drugs loaded within
and without exosomes, which were compared. The data showed
signiﬁcant therapeutic efﬁcacy in the zebraﬁsh brain model treated
with exosomes loaded doxorubicin compared to doxorubicin
alone. Overall, the results obtained from the study showed the
potential of exosomes to deliver small molecule drugs across the
BBB to treat both brain cancers and neurological disorders.
Since these exosomes were small and native to the animals, the
researchers were able to avoid phagocytosis, fuse with the cell
membrane, and bypass the engulfment by lysosomes. The fact
that exosomes are a natural product of the body resulted in a
low immune response. Most chemotherapeutic agents, such as
doxorubicin, have low solubility and toxicity due to nonspeciﬁc
tissue targeting and a short half-life, which leads to the poor
efﬁcacy of the drugs. Another study was performed using
exosomes to deliver the antitumor agent doxorubicin into a mouse
tumor tissue model both in vitro and in vivo54. In this study,
exosomes were isolated and puriﬁed from pEGFP-C1-RVG-
Lamp2b plasmid that contained immature mouse dendritic cells
through centrifugation and ultraﬁltration. The isolated exosomes
were characterized using nanoparticle tracking analysis loaded
with doxorubicin through electroporation. The ability of exosomes
to deliver doxorubicin was tested by facilitating the fusion of
encapsulated exosomes with a human breast cancer MDA-MB-231
cells. Fluorescence measurements and overlap clearly showed
successful exosome delivery into the cells. The inhibition of
in vitro cancer proliferation was measured by treating MDA-
MB-231 with these exosomes and determining cell viability using
cell counting kit-8 (CCK-8) assays. The results showed that cellinhibition by doxorubicin encapsulated exosomes was similar to
inhibition using free doxorubicin, indicating the anticancer ability
of doxorubicin encapsulated exosomes. The ability of exosomes to
speciﬁcally deliver doxorubicin to tumor tissue and inhibit tumor
growth in vivo was analyzed by injecting the ﬂuorescent exo-
somes. The data showed an accumulation of doxorubicin contain-
ing exosomes speciﬁcally at the targeted organ and a major
suppression of tumor growth. Collectively, the results conﬁr-
med the ability of exosomes to target and deliver doxorubicin
efﬁciently.2.2. Exosomes as drug delivery vehicles for proteins
In addition to delivering small molecules, exosomes are also used
to deliver large molecules such as proteins. A recent study, for
example, showed that exosomes loaded with the antioxidant
protein catalase was successfully delivered across the BBB,
resulting in an improved disease state in PD56. PD is associated
with inﬂammation in the brain, microglia activation, and the
secretion of reactive oxygen species (ROS)69–71. Patients with PD
are shown to have lower levels of antioxidant enzymes like
catalase and superoxide dismutase, which helps in oxidative stress
and the inhibition of neurodegeneration72–74. Catalase is an
enzyme that can deactivate one million free radicals per second
per molecule in a single cycle of catalytic reaction56. Like many
other drugs, the delivery of catalase across the BBB is a hurdle,
but delivery of catalase to the brain using exosomes seems a
promising option for PD therapy.
In this study, catalase was incorporated into exosomes using
multiple methods: incubation at room temperature with or without
the use of saponin permeabilization, freeze–thaw cycles, sonica-
tion, and extrusion procedures. Analysis by western blot showed
that sonication and extrusion techniques resulted in the most
efﬁcient incorporation of catalase into exosomes. To conﬁrm the
delivery of catalase, exosomes were labeled with lipophilic
ﬂuorescent dye and incubated with a cell line derived from a
pheochromocytoma of the rat adrenal medulla (PC12 cells).
Confocal images conﬁrmed the uptake of DIL (1,10-dioctadecyl-
3,3,30,30-tetramethylindocarbocyanine perchlorate)-labeled exo-
somes in PC12 cells. The elimination of ROS in in vitro–activated
macrophages was also observed when exosomal catalase was
added, suggesting the successful exosomal delivery of catalase and
the neutralization of ROS. Further visualization experiments were
Exosomes as therapeutic drug carriers and delivery vehicles 293performed to understand the transportation of exosomes in
inﬂamed brain tissues in a PD mouse model using confocal
microscopy. Results showed the wide distribution of exosomes
in the brain, indicating the ability of exosomes to target and deliver
their cargo to the brain tissue. Overall, this study showed various
methods used to isolate exosomes and the ability of exosomes to
carry catalase across BBB in the treatment of PD.2.3. Exosomes as drug delivery vehicles for nucleic acids
It has also been shown that exosomes naturally carry nucleic acids,
such as DNA and RNA, to targeted cells, inducing genetic
modiﬁcations in both biological and pathogenic processes. These
features of exosomes became a major interest in treatment
strategies involving genetic therapy, and studies using exosomes
as drug delivery systems have been conducted to deliver ther-
apeutic genetic materials that alter gene expression in certain
diseases and improve genetic therapy.2.3.1. Small interference RNA (siRNA)
In genetic therapy, siRNA is used to disrupt genes of interest.
However, these siRNA have low stability and tend to degrade
quickly in the systemic circulation. Exosomes, however, can act as
therapeutic vehicles that help in the protection and delivery of
siRNA to the targeted cells. However, determining the utility of
exosomes to deliver exogenous siRNA still requires much more
investigation and understanding. Several studies have been con-
ducted to test the usefulness of exosomes as therapeutic vehicles to
successfully deliver exogenous genetic material and their post-
delivery functionality, and the ﬁrst published study, conducted by
Alvarez-Erviti et al.75, used exosomes to deliver siRNA to the
brains of mice. After this ﬁrst study, another group examined the
delivery of siRNA to T cells and monocytes using human
exosomes57. There is a signiﬁcant shortage of therapeutic delivery
vehicles for genetic materials that are safe, efﬁcient, and target
speciﬁc. The purpose of that study was to ﬁnd a method to deliver
vectors in gene therapy. Exosomes were used because they have
the natural ability to deliver RNA from cell to cell and are non-
immunogenic to the host. The purpose of the study was mainly to
ﬁnd a suitable method to deliver vectors in gene therapy
In the study, exosomes were isolated using differential centrifu-
gation from various cell types, including the peripheral blood of
healthy donors, lung cancer cells TB-177, and HeLa cells. Then,
siRNA was introduced into exosomes using two different methods:
chemical transfection and electroporation. The results showed that
chemical transfection was unsuitable and the data were inconclu-
sive. Analysis by western and northern blotting, confocal micro-
scopy, and ﬂow cytometry suggested the successful introduction of
siRNA into exosomes. Plasma exosomes were transfected with
Alexa Fluor 488-tagged siRNA against mitogen-activated protein
kinase 1 (MAPK-1) using electrophoresis and then co-cultured with
monocytes and lymphocytes isolated from the peripheral blood of
healthy donors. siRNA ﬂorescence by exosomes was detected in the
cytoplasm of the recipient cells. Flow cytometry conﬁrmed the
effective delivery of siRNA into peripheral blood mononuclear cells
(PBMC). Additionally, immunoblotting was performed to evaluate
the ability of delivered siRNA with exosome to have caused post-
transcriptional gene-silencing in recipient cells. Results showed a
decrease in MAPK-1 expression by exosomal siRNA, indicating
down regulation of the speciﬁc gene and successful gene silencing.And the research clearly showed that exosomes can be used as
delivery vehicles in genetic therapy57.
A similar in vitro study also showed the ability of exosomes to
deliver siRNA to human cells. RAD51 (a eukaryote gene protein
that assists in repair of DNA double strand breaks) has previously
been shown as a potential target to repress the growth of
abnormally proliferating cells in cancer76. In an in vitro study,
exosomes-delivered siRNA against RAD51 was used, and its
functionality after delivery to human cells was demonstrated.
Further, exosomes were isolated from HeLa cells by ultracentri-
fugation and loaded with Alexa-ﬂour 488-labeled siRNA using
chemical treatment and then further co-cultured with recipient cells
(HeLa and HT1080 cells). The successful delivery efﬁciency of
siRNA by exosomes was conﬁrmed by confocal microscopy and
ﬂow cytometry. The study also investigated whether delivered
siRNA were efﬁcient and whether they down-regulated the
expression of RAD51 and RAD52. Experimental results from
western blot analysis showed a considerable reduction in RAD51
and RAD52 protein levels, indicating successful down-regulation
of this speciﬁc gene58. Largely, these results showed the potential
of exosomes as therapeutic vehicles by keeping the cargoes they
carry functional. However, exosomes derived from different cell
types have slightly different compositions and functions. Exo-
somes derived from endothelial cells are associated with vascular
inﬂammation and atherosclerosis. However, little is known about
their ability to deliver exogenous contents. Given this context,
another study has investigated the use of endothelial exosomes to
deliver siRNA to endothelial cells59. Exosomes were isolated from
endothelial cells by combining ﬁltration and ultracentrifugation
techniques, and their interactions with endothelial cells were
evaluated. Exosomes were then loaded with siRNA using electro-
poration, and the functionality of endothelial exosomes to deliver
siRNA to endothelial cells was tested. Exosomes loaded with
siRNA were incubated with luciferase-expressing endothelial cells.
siRNA was designed to silence a vector encoding for the
production of luciferase (pGL2) in transiently-transfected endothe-
lial cells with pGL2. The results showed signiﬁcantly lower
luciferase expression in endothelial exosomes carrying siRNA
compared to the control groups. This indicates that endothelial
exosomes can also deliver exogenous agents to cells in vitro and
are functional at the targeted site.2.3.2. miRNA
miRNA is short form of non-coding RNA and with non-protein
nucleotides found in eukaryotic cells. These miRNAs bind to
complementary sequences on targeted mRNA and control post-
transcriptional gene expression77,78. Exosomes are known to
naturally carry miRNA and, hence, it is logical to use exosomes
as a therapeutic vehicle to deliver miRNA to targeted cells. Ohno
et al.60, for example, conducted a study using exosomes to deliver
miRNA that targeted epidermal growth factor receptor (EGFR) in
breast cancer cells. Various human tumors originated from
epithelial showed an elevated level of EGFR expression, suggest-
ing the possibility of using EGFR ligand as cancer drug targets79.
There has also been evidence suggesting that miRNA, such as
let-7a, functions as a tumor suppressor and inhibits the growth of
cancer by reducing RAS and high-mobility group AT-hook protein
(HMGA2) expression. In the study, epidermal growth factor
(EGF) and EGFR-speciﬁc peptide (GE11), which binds speciﬁ-
cally to EGFR, were incorporated onto the surfaces of exosomes
that carried let-7a in order to deliver let-7a to EGFR-expressing
Dinh Ha et al.294cancer tissue60. To create GE11- and EPF-positive exosomes, a
pDisplay vector encoding GE11 or EGF was transfected into
HEK-293 cells. Exosomes were then isolated from the cloned cells
by differential centrifugation. The expression of GE11 or EGF on
the surface of the exosomes was examined using anti-
hemagglutinin and western blot analysis. Fluorescence-activated
cell sorting and anti-Myc-tag antibodies were also used to conﬁrm
the presence of GE11 or EGF on the surface of the exosomes. The
ability of GE11- or EGF-positive exosomes to bind to EGFR in
various breast cancer cell lines, including HCC70, HCC1954 and
MCF-7, were then tested. Exosomes were labeled with PKH67 dye
to show the engulfment of exosomes into the recipient cells.
Various experiments were then conducted to verify that the
exosomes were taken up by an EGFR-dependent mechanism.
These results showed that the modiﬁed exosomes were taken into
recipient cells. In addition, the researchers assessed whether GE11-
or EGF-positive exosomes affected cell growth in vitro by
performing cell proliferation assays. They found that GE11-
positive exosomes did not stimulate EGFR signaling like EGF
did and, thus, GE-11 positive exosomes might be more suitable
than EGF-positive exosomes.
In in vivo experiments, lethal-7 gene (let-7a) was introduced into
GE11 exosomes by the lipofection method. Then, GE11 exosomes
containing let-7a were intravenously injected into tumor-bearing
mice. Since previous studies showed let-7a inhibited tumor growth
by reducing the expression level of RAS and HMGA2, the
expressions of these genes were examined in injected tumor-
bearing mice, using real-time reverse transcription-PCR analysis,
immunoblotting, and immunostaining. The results showed that
let-7a delivered by GE11-exosomes strongly inhibited the expres-
sion of HMGA2 in cancer cells. This indicated that exosomes do
successfully deliver their cargo to the target cells, showing promis-
ing characteristics for drug delivery60.2.4. Major advantages and disadvantages
Many of the newer drug candidates such as proteins and nucleic
acids are highly unstable inside in vivo environment posing
signiﬁcant challenges to successful therapeutic outcomes. Given
the problems associated with many of the current nanoparticulate
delivery systems, exosomes as a mimic of “nature's delivery
systems” allows for delivery of these biological molecules.
Because of the inherent small size and nature's own cellular
product these vehicles can avoid phagocytosis or degradation by
macrophages and can also circulate for extended periods of time
within the body. Unlike typical nanoparticulate systems such as
liposomes or polymeric nanoparticles, exosomes can potentially
avoid the endosomal pathway and lysosomal degradation, and also
deliver cargoes directly into the cytoplasm. By virtue of avoiding
the endosomal pathway transfection efﬁciency for molecules such
as siRNA can be enhanced80. They are naturally stable and have
inherent targeting properties depending on the composition of the
exosomes. One of the signiﬁcant advantages of these drug delivery
vehicles also includes their ability to cross BBB2,81. Inadequate
understanding of exosomes nature and the role in overall health
and disease condition make it complicated to predict long-term
safety and therapeutic effect. In vivo trafﬁcking, biological fate and
their impact on targeted organs need to be understood more
thoroughly. There exist many challenges in a clear understanding
of exosomes with regard to therapeutic cargo loading and
assembly for drug delivery.Currently, there is no distinct optimal puriﬁcation technique for
isolation of exosomes with high purity82. The isolation methods
yield low quantities of exosomes and their large scale production
for clinical studies and post drug approval is expensive83. It is
highly likely that future clinical use demands hybrid type of
exosome designs84, and when combined with therapeutic cargos
they may show undesirable effects. If such systems are designed
their clinical efﬁcacy and safety parameters needs to be thoroughly
characterized. To functionalize exosomes ligands are attached to
the surface through chemical conjugation and these active target-
ing molecular combinational product and methods needs to be
investigated. Integrative studies using therapeutic cargo and
functional exosomes or hybrid exosomes mimetic are becoming
very critical. Even though extensive biology is already known,
exosomes comprise heterogeneous components and may show
immunogenicity (immunostimulatory or immunospressive) effects
based on nature of parental donor cells. Exosomes involvement in
tumor progression or help membrane antigens release that help in
tumor growth is a huge concern. Exosomes that carry caspase-3
may also inhibit cell death by apoptosis or enhance tumor cell
survival by preventing chemotherapeutics drug accumulation51.
One of the approaches is to design artiﬁcial exosomes or exosome
mimetics that has the ability to overcome the potential disadvan-
tages such as unwanted immune reactions50.3. Conclusions
Exosomes provide an enormous promise and a fresh therapeutic
area for delivery of different synthetic and biological molecules in
cellular therapy. Exosomes as drug delivery vehicles offer a major
advantage as there is no unwanted accumulation or homing of
exosomes in the liver and (or) avoid the ﬁrst pass metabolic effect,
before reaching target sites. The well characterized exosomes
along with long-term safety and natural ability to carry inter-
cellular nucleic acids and therapeutic molecules, across mem-
branes difﬁcult to cross such as BBB, would have major practical
signiﬁcance. Before these drug delivery systems become a
therapeutic reality, component characterization and immune reac-
tions need to be clearly understood.References
1. Lai RC, Yeo RWY, Tan KH, Lim SK. Exosomes for drug delivery—a
novel application for the mesenchymal stem cell. Biotechnol Adv
2013;31:543–51.
2. Kooijmans SA, Vader P, van Dommelen SM, van Solinge WW,
Schiffelers RM. Exosome mimetics: a novel class of drug delivery
systems. Int J Nanomed 2012;7:1525–41.
3. Schiller M, Bekeredjian-Ding I, Heyder P, Blank N, Ho AD, Lorenz
HM. Autoantigens are translocated into small apoptotic bodies during
early stages of apoptosis. Cell Death Differ 2008;15:183–91.
4. Gregory CD, Pound JD. Microenvironmental inﬂuences of apoptosis
in vivo and in vitro. Apoptosis 2010;15:1029–49.
5. Johnstone RM. Revisiting the road to the discovery of exosomes.
Blood Cells Mol Dis 2005;34:214–9.
6. Simons M, Raposo G. Exosomes-vesicular carriers for intercellular
communication. Curr Opin Cell Biol 2009;21:575–81.
7. Qin J, Xu Q. Functions and applications of exosomes. Acta Pol Pharm
2014;71:537–43.
8. Urbanelli L, Magini A, Buratta S, Brozzi A, Sagini K, Polchi A, et al.
Signaling pathways in exosomes biogenesis, secretion and fate. Genes
2013;4:152–70.
Exosomes as therapeutic drug carriers and delivery vehicles 2959. Katzmann DJ, Odorizzi G, Emr SD. Receptor downregulation and
multivesicular-body sorting. Nat Rev Mol Cell Biol 2002;3:893–905.
10. Février B, Raposo G. Exosomes: endosomal-derived vesicles shipping
extracellular messages. Curr Opin Cell Biol 2004;16:415–21.
11. Raiborg C, Rusten TE, Stenmark H. Protein sorting into multivesicular
endosomes. Curr Opin Cell Biol 2003;15:446–55.
12. Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P,
et al. Analysis of ESCRT functions in exosome biogenesis, composi-
tion and secretion highlights the heterogeneity of extracellular vesicles.
J Cell Sci 2013;126:5553–65.
13. Tamai K, Tanaka N, Nakano T, Kakazu E, Kondo Y, Inoue J, et al.
Exosome secretion of dendritic cells is regulated by Hrs, an ESCRT-0
protein. Biochem Biophys Res Commun 2010;399:384–90.
14. Gross JC, Chaudhary V, Bartscherer K, Boutros M. Active Wnt
proteins are secreted on exosomes. Nat Cell Biol 2012;14:1036–45.
15. Hoshino D, Kirkbride KC, Costello K, Clark ES, Sinha S, Grega-
Larson N, et al. Exosome secretion is enhanced by invadopodia and
drives invasive behavior. Cell Rep 2013;5:1159–68.
16. Abrami L, Brandi L, Moayeri M, Brown MJ, Krantz BA, Leppla SH,
et al. Hijacking multivesicular bodies enables long-term and
exosome-mediated long-distance action of anthrax toxin. Cell Rep
2013;5:986–96.
17. Kowal J, Tkach M, Théry C. Biogenesis and secretion of exosomes.
Curr Opin Cell Biol 2014;29:116–25.
18. Heijnen HFG, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated
platelets release two types of membrane vesicles: microvesicles by
surface shedding and exosomes derived from exocytosis of multi-
vesicular bodies and α-granules. Blood 1999;94:3791–9.
19. van Niel G, Charrin S, Simoes S, Romao M, Rochin L, Saftig P, et al.
The tetraspanin CD63 regulates ESCRT-independent and-dependent
endosomal sorting during melanogenesis. Dev Cell 2011;21:708–21.
20. Denzer K, Kleijmeer MJ, Heijnen H, Stoorvogel W, Geuze HJ.
Exosome: from internal vesicle of the multivesicular body to inter-
cellular signaling device. J Cell Sci 2000;113:3365–74.
21. Lamparski HG, Metha-Damani A, Yao J-Y, Patel S, Hsu D-H, Ruegg
C, et al. Production and characterization of clinical grade exosomes
derived from dendritic cells. J Immunol Methods 2002;270:211–26.
22. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D,
et al. Eradication of established murine tumors using a novel cell-free
vaccine: dendritic cell derived exosomes. Nat Med 1998;4:594–600.
23. Simpson RJ, Mathivanan S. Extracellular microvesicles: the need for
internationally recognised nomenclature and stringent puriﬁcation
criteria. J Proteom Bioinform 2012;5:2.
24. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes:
current knowledge of their composition, biological functions, and
diagnostic and therapeutic potentials. Biochim Biophys Acta
2012;1820:940–8.
25. Batrakova EV, Kim MS. Using exosomes, naturally-equipped nano-
carriers, for drug delivery. J Control Release 2015;219:396–405.
26. Théry C, Duban L, Segura E, Véron P, Lantz O, Amigorena S. Indirect
activation of naïve CD4þ T cells by dendritic cell-derived exosomes.
Nat Immunol 2002;3:1156–62.
27. Kalani A, Tyagi A, Tyagi N. Exosomes: mediators of neurodegenera-
tion, neuroprotection and therapeutics. Mol Neurobiol 2014;49:
590–600.
28. Subra C, Laulagnier K, Perret B, Record M. Exosome lipidomics
unravels lipid sorting at the level of multivesicular bodies. Biochimie
2007;89:205–12.
29. Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A,
et al. Microenvironmental pH is a key factor for exosome trafﬁc in
tumor cells. J Biol Chem 2009;284:34211–22.
30. Piccin A, Murphy WG, Smith OP. Circulating microparticles: patho-
physiology and clinical implications. Blood Rev 2007;21:157–71.
31. Johnstone RM, Adam M, Hammond J, Orr L, Turbide C. Vesicle
formation during reticulocyte maturation. Association of plasma
membrane activities with released vesicles (exosomes). J Biol Chem
1987;262:9412–20.32. Johnstone RM, Mathew A, Mason AB, Teng K. Exosome formation
during maturation of mammalianand avian reticulocytes: evidence that
exosome release is a major route for externalization of obsolete
membrane proteins. J Cell Physiol 1991;147:27–36.
33. Morelli AE, Larregina AT, Shufesky WJ, Sullivan MLG, Stolz DB,
Papworth GD, et al. Endocytosis, intracellular sorting, and processing
of exosomes by dendritic cells. Blood 2004;104:3257–66.
34. De Toro J, Herschlik L, Waldner C, Mongini C. Emerging roles of
exosomes in normal and pathological conditions: new insights for
diagnosis and therapeutic applications. Front Immunol 2015;6:203.
35. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO.
Exosome-mediated transfer of mRNAs and microRNAs is a novel
mechanism of genetic exchange between cells. Nat Cell Biol
2007;9:654–9.
36. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Curry WT,
et al. Glioblastoma microvesicles transport RNA and proteins that
promote tumour growth and provide diagnostic biomarkers. Nat Cell
Biol 2008;10:1470–6.
37. Laulagnier K, Grand D, Dujardin A, Hamdi S, Vincent-Schneider H,
Lankar D, et al. PLD2 is enriched on exosomes and its activity is
correlated to the release of exosomes. FEBS Lett 2004;572:11–4.
38. Aharon A, Microparticles Brenner B. thrombosis and cancer. Best
Pract Res Clin Haematol 2009;22:61–9.
39. Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund
E, Ringnér M, et al. Exosomes reﬂect the hypoxic status of glioma
cells and mediate hypoxia-dependent activation of vascular cells
during tumor development. Proc Natl Acad Sci U S A
2013;110:7312–7.
40. Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer
exosomes trigger ﬁbroblast to myoﬁbroblast differentiation. Cancer
Res 2010;70:9621–30.
41. Rana S, Malinowska K, Zöller M. Exosomal tumor microRNA
modulates premetastatic organ cells. Neoplasia 2013;15:281–95.
42. Ghidoni R, Benussi L, Binetti G. Exosomes: the Trojan horses of
neurodegeneration. Med Hypotheses 2008;70:1226–7.
43. Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L,
Breakeﬁeld XO, et al. Prostate cancer-derived urine exosomes: a novel
approach to biomarkers for prostate cancer. Br J Cancer
2009;100:1603–7.
44. Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L. Intracellular
and extracellular microRNAs in breast cancer. Clin Chem 2011;57:
18–32.
45. Li JH, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB,
Morin PJ. Claudin-containing exosomes in the peripheral circulation of
women with ovarian cancer. BMC Cancer 2009;9:244.
46. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S.
Advances and challenges of liposome assisted drug delivery. Front
Pharmacol 2015;6:286.
47. Agrawal U, Sharma R, Gupta M, Vyas SP. Is nanotechnology a boon
for oral drug delivery? Drug Discov Today 2014;19:1530–46.
48. Raemdonck K, Braeckmans K, Demeester J, De Smedt SC. Merging
the best of both worlds: hybrid lipid-enveloped matrix nanocomposites
in drug delivery. Chem Soc Rev 2014;43:444–72.
49. Li C, Zhang J, Zu YJ, Nie SF, Cao J, Wang Q, et al. Biocompatible
and biodegradable nanoparticles for enhancement of anti-cancer
activities of phytochemicals. Chin J Nat Med 2015;13:641–52.
50. Aryani A, Denecke B. Exosomes as a nanodelivery system: a key to
the future of neuromedicine? Mol Neurobiol 2016;53:818–34.
51. Turturici G, Tinnirello R, Sconzo G, Geraci F. Extracellular membrane
vesicles as a mechanism of cell-to-cell communication: advantages and
disadvantages. Am J Physiol Cell Physiol 2014;306:C621–33.
52. Rani S, Ritter T. The exosome-a naturally secreted nanoparticle and its
application to wound healing. Adv Mater 2015 Dec 17. Available
from: 10.1002/adma.201504009.
53. Sun DM, Zhuang XY, Xiang XY, Liu YL, Zhang SY, Liu CR, et al. A
novel nanoparticle drug delivery system: the anti-inﬂammatory activity
of curcumin is enhanced when encapsulated in exosomes. Mol Ther
2010;18:1606–14.
Dinh Ha et al.29654. Tian YH, Li SP, Song J, Ji TJ, Zhu MT, Anderson GJ, et al. A
doxorubicin delivery platform using engineered natural membrane vesicle
exosomes for targeted tumor therapy. Biomaterials 2014;35:2383–90.
55. Yang TZ, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, et al.
Exosome delivered anticancer drugs across the blood–brain barrier for
brain cancer therapy in Danio Rerio. Pharm Res 2015;32:2003–14.
56. Haney MJ, Klyachko NL, Zhao YL, Gupta R, Plotnikova EG, He ZJ,
et al. Exosomes as drug delivery vehicles for Parkinson's disease
therapy. J Control Release 2015;207:18–30.
57. Wahlgren J, Karlson TDL, Brisslert M, Sani FV, Telemo E,
Sunnerhagen P, et al. Plasma exosomes can deliver exogenous short
interfering RNA to monocytes and lymphocytes. Nucleic Acids Res
2012;40:e130.
58. Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV,
Filatov MV. Exosomes are natural carriers of exogenous siRNA to
human cells in vitro. Cell Commun Signal 2013;11:1186–96.
59. Banizs AB, Huang T, Dryden K, Berr SS, Stone JR, Nakamoto RK,
et al. In vitro evaluation of endothelial exosomes as carriers for small
interfering ribonucleic acid delivery. Int J Nanomed 2014;9:4223–30.
60. Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N,
et al. Systemically injected exosomes targeted to EGFR deliver
antitumor microRNA to breast cancer cells. Mol Ther 2013;21:185–91.
61. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how
many ways can curry kill tumor cells selectively? AAPS J
2009;11:495–510.
62. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcu-
min, the anti-inﬂammatory agent, against neurodegenerative, cardio-
vascular, pulmonary, metabolic, autoimmune and neoplastic diseases.
Int J Biochem Cell Biol 2009;41:40–59.
63. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB.
Curcumin and cancer: an “old-age” disease with an “age-old” solution.
Cancer Lett 2008;267:133–64.
64. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara
AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with
advanced pancreatic cancer. Clin Cancer Res 2008;14:4491–9.
65. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavail-
ability of curcumin: problemsand promises. Mol Pharm 2007;4:807–18.
66. Pardridge WM. Drug transport across the blood–brain barrier. J Cereb
Blood Flow Metab 2012;32:1959–72.
67. Peng Q, Zhang S, Yang Q, Zhang T, Wei XQ, Jiang L, et al.
Preformed albumin corona, a protective coating for nanoparticles
based drug delivery system. Biomaterials 2013;34:8521–30.
68. Yoshida K, Burton GF, McKinney JS, Young H, Ellis EF. Brain and
tissue distribution of polyethylene glycol-conjugated superoxide dis-
mutase in rats. Stroke 1992;23:865–9.69. Veronese FM, Caliceti P, Schiavon O, Sergi M. Polyethylene glycol-
superoxide dismutase, a conjugate in search of exploitation. Adv Drug
Deliv Rev 2002;54:587–606.
70. Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant
therapy in Parkinson's disease. Prog Neurobiol 1996;48:1–19.
71. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos
H, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc
Natl Acad Sci USA 2003;100:6145–50.
72. Ambani LM, Van Woert MH, Murphy S. Brain peroxidase and
catalase in Parkinson disease. Arch Neurol 1975;32:114–8.
73. Riederer P, Soﬁc E, Rausch WD, Schmidt B, Reynolds GP, Jellinger
K, et al. Transition metals, ferritin, glutathione, and ascorbic acid in
parkinsonian brains. J Neurochem 1989;52:515–20.
74. Abraham S, Soundararajan CC, Vivekanandhan S, Behari M. Ery-
throcyte antioxidant enzymes in Parkinson’s disease. Indian J Med Res
2005;121:111–5.
75. Alvarez-Erviti L, Seow Y, Yin HF, Betts C, Lakhal S, Wood MJA.
Delivery of siRNA to the mouse brain by systemic injection of targeted
exosomes. Nat Biotechnol 2011;29:341–5.
76. Shtam TA, Varfolomeeva EY, Semenova EV, Filatov MV. Role of
human RAD51 recombinase in the cycle checkpoint and survival of a
cell. Cell Tissue Biol 2008;2:463–7.
77. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and
function. Cell 2004;116:281–97.
78. Bartel DP. MicroRNAs: target recognition and regulatory functions.
Cell 2009;136:215–33.
79. Woodburn JR. The epidermal growth factor receptor and its inhibition
in cancer therapy. Pharmacol Ther 1999;82:241–50.
80. Mehrotra N, Tripathi RM. Short interfering RNA therapeutics:
nanocarriers, prospects and limitations. IET Nanobiotechnol
2015;9:386–95.
81. Tran T-H, Mattheolabakis G, Aldawsari H, Amiji M. Exosomes as
nanocarriers for immunotherapy of cancer and inﬂammatory diseases.
Clin Immunol 2015;160:46–58.
82. Petersen KE, Manangon E, Hood JL, Wickline SA, Fernandez DP,
Johnson WP, et al. A review of exosome separation techniques and
characterization of B16-F10 mouse melanoma exosomes with AF4-
UV-MALS-DLS-TEM. Anal Bioanal Chem 2014;406:7855–66.
83. Taylor DD, Shah S. Methods of isolating extracellular vesicles impact
down-stream analyses of their cargoes. Methods 2015;87:3–10.
84. Rana S, Yue SJ, Stadel D, Zöller M. Toward tailored exosomes: the
exosomal tetraspanin web contributes to target cell selection. Int J
Biochem Cell Biol 2012;44:1574–84.
